| Peter S. Kim | |
|---|---|
| Education | Ph.D., Biochemistry |
| Alma mater | Stanford University Cornell University |
| Employer | Merck & Co., Inc. |
| Known for | Discovering how proteins cause cell membranes to fuse |
| Title | President, Merck Research Laboratories |
| Website | |
| Peter S. Kim Research Papers | |
Peter S. Kim is president[1] of Merck Research Laboratories (MRL).[2] Kim was promoted to this position in January 2003. In this role he oversees all of Merck's drug and vaccine research and development activities.[3]
Kim, a Korean-American, joined the Company in 2001 as executive vice president, Research and Development for MRL.
Kim trained as a structural biologist. He has studied at Stanford University, where he earned his doctorate in biochemistry, and Cornell University, graduating with distinction[4] in chemistry. While at Stanford, he was also a Medical Scientist Training Program Fellow.
Later, Kim worked as a Professor of Biology at Massachusetts Institute of Technology (MIT), and was a Member of the Whitehead Institute and an Investigator at the Howard Hughes Medical Institute.
Kim has a special interest in HIV / AIDS research and designed compounds that stop membrane fusion by the AIDS virus, thereby preventing it from infecting cells. Kim also served as a member of the National Institutes of Health (NIH) Advisory Committee to develop an AIDS vaccine.[4]
His research and work in improving human health has earned Kim numerous awards and other recognition. Some of these honors are noted in the following sections.
Contents |